Stocks News

LAST PRICE
18.4800
TODAY'S CHANGE (%)
Trending Up0.1000 (0.5441%)

Bid / Lots
18.3600/ 8
Ask / Lots
18.4800/ 8
Open / Previous Close
18.0800 / 18.3800
Day Range
Low 18.0400
High 18.6600
52 Week Range
Low 2.8700
High 23.4000
Volume
73,950
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- JonesTrading Initiates Capricor Therapeutics at Buy Rating With $40 Price Target, from 8:28AM ET on Monday Nov 18, 2024 by MT Newswires
  8:28AM ET on Monday Nov 18, 2024 by MT Newswires
  Companies Mentioned: CAPR
  08:28 AM EST, 11/18/2024 (MT Newswires) -- Capricor Therapeutics (CAPR) has an average buy rating and a price target range of $25 to $77, according to analysts polled by Capital IQ. ...
- DJ Capricor Therapeutics Initiated at Buy by Jones Trading, from 7:29AM ET on Monday Nov 18, 2024 by Dow Jones
  7:29AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: CAPR
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CAPR/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 18, 2024 07:29 ET (12:29 GMT)
Nov 14, 2024
- DJ Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co., from 1:27PM ET on Thursday Nov 14, 2024 by Dow Jones
  1:27PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: CAPR
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CAPR/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 14, 2024 13:27 ET (18:27 GMT)
- DJ Capricor Therapeutics Is Maintained at Overweight by Cantor Fitzgerald, from 9:09AM ET on Thursday Nov 14, 2024 by Dow Jones
  9:09AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: CAPR
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CAPR/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 14, 2024 09:09 ET (14:09 GMT)
Nov 13, 2024
- Capricor Therapeutics Q3 Net Loss Widens, Revenue Declines From Year-Ago Levels, from 4:57PM ET on Wednesday Nov 13, 2024 by MT Newswires
  4:57PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: CAPR
  04:57 PM EST, 11/13/2024 (MT Newswires) -- Capricor Therapeutics (CAPR) late Wednesday reported a Q3 net loss of $0.38 per diluted share compared with a loss of $0.25 a year earlier. Analysts polled by Capital IQ expected a loss of $0.36. Revenue fo...

Nov 15, 2024
- 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting(R) 2024, from 8:05AM ET on Friday Nov 15, 2024 by Dow Jones
  8:05AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: ETNB
Nov 13, 2024
- Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination, from 9:47AM ET on Wednesday Nov 13, 2024 by MT Newswires
  9:47AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: RXRX, EXAI
- Press Release: Recursion and Exscientia Shareholders Approve the Proposed Combination, from 9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones
  9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: RXRX, EXAI
- 89bio Prices $125 Million Offering, from 5:13AM ET on Wednesday Nov 13, 2024 by MT Newswires
  5:13AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: ETNB
- *DJ 89bio Prices $125.0M Upsized Public Offering of Stock, Warrants >ETNB, from 12:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
  12:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: ETNB
Nov 12, 2024
- 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants, from 11:58PM ET on Tuesday Nov 12, 2024 by Dow Jones
  11:58PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: ETNB
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: ETNB
Nov 11, 2024
- DJ 89bio Price Target Maintained With a $29.00/Share by HC Wainwright & Co., from 7:36AM ET on Monday Nov 11, 2024 by Dow Jones
  7:36AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: ETNB
Nov 8, 2024
- DJ Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 2:14PM ET on Friday Nov 08, 2024 by Dow Jones
  2:14PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RLAY
- DJ 89bio Is Maintained at Strong Buy by Raymond James, from 12:45PM ET on Friday Nov 08, 2024 by Dow Jones
  12:45PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: ETNB

Capricor Therapeutics Inc
NASDAQ:CAPRUnited States

Search Criteria

Yesterday

JonesTrading Initiates Capricor Therapeutics at Buy Rating With $40 Price Target, from 8:28AM ET on Monday Nov 18, 2024 by MT Newswires

DJ Capricor Therapeutics Initiated at Buy by Jones Trading, from 7:29AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 14, 2024

DJ Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co., from 1:27PM ET on Thursday Nov 14, 2024 by Dow Jones

DJ Capricor Therapeutics Is Maintained at Overweight by Cantor Fitzgerald, from 9:09AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Capricor Therapeutics Q3 Net Loss Widens, Revenue Declines From Year-Ago Levels, from 4:57PM ET on Wednesday Nov 13, 2024 by MT Newswires

Peers Headlines

Nov 15, 2024

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting(R) 2024, from 8:05AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 13, 2024

Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination, from 9:47AM ET on Wednesday Nov 13, 2024 by MT Newswires

Press Release: Recursion and Exscientia Shareholders Approve the Proposed Combination, from 9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones

89bio Prices $125 Million Offering, from 5:13AM ET on Wednesday Nov 13, 2024 by MT Newswires

*DJ 89bio Prices $125.0M Upsized Public Offering of Stock, Warrants >ETNB, from 12:01AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants, from 11:58PM ET on Tuesday Nov 12, 2024 by Dow Jones

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones

Nov 11, 2024

DJ 89bio Price Target Maintained With a $29.00/Share by HC Wainwright & Co., from 7:36AM ET on Monday Nov 11, 2024 by Dow Jones

Nov 8, 2024

DJ Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 2:14PM ET on Friday Nov 08, 2024 by Dow Jones

DJ 89bio Is Maintained at Strong Buy by Raymond James, from 12:45PM ET on Friday Nov 08, 2024 by Dow Jones